News

Nasdaq6mon
Neurocrine's CRENESSITY Gains FDA Approval For Treating Congenital Adrenal Hyperplasia - Nasdaq
Neurocrine's CRENESSITY Gains FDA Approval For Treating Congenital Adrenal Hyperplasia December 13, 2024 — 07:52 pm EST Written by RTTNews.com for RTTNews -> ...
Business Insider1y
Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia - Markets Insider
SAN DIEGO, Dec. 5, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA ...
BioWorld6mon
Neurocrine’s hyperplasia drug approved by the FDA | BioWorld
A preview of the next edition of BioWorld, Dec. 16, 2024. While Spruce Biosciences Inc.’s tildacerfont missed its phase II primary endpoint in classic congenital adrenal hyperplasia (CAH) last March, ...
Business Insider3y
Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022 ...
SAN DIEGO, March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment p ...
Nasdaq4y
BridgeBio Gets FDA Fast Track Designation For Gene Therapy For Congenital Adrenal Hyperplasia - Nasdaq
(RTTNews) - BridgeBio Pharma Inc. (BBIO) said that the U.S. Food and Drug Administration granted Fast Track designation to BBP-631, an investigational adeno-associated virus 5 gene therapy ...
BioWorld1y
Phase III with Neurocrine’s crinecerfont succeeds in CAH
A preview of the next edition of BioWorld, Sept. 12, 2023. Neurocrine Biosciences Inc. unveiled positive top-line data from the phase III study called Cahtalyst testing the efficacy, safety and ...
Healio2y
Prescribed hydrocortisone dose shrinks with weight gain in congenital adrenal hyperplasia - Healio
Clinicians are prescribing children with congenital adrenal hyperplasia decreasing dosages of hydrocortisone per body surface area as weight and BMI increase, without worse treatment outcomes ...
FierceBiotech10y
Neurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia
The Company has also been informed by the FDA that the NBI-77860 clinical development program would be placed on partial clinical hold. About Classic Congenital Adrenal Hyperplasia (CAH) Classic ...
WebMD1y
Nonclassical Congenital Adrenal Hyperplasia (NCAH): Symptoms and Treatment - WebMD
Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical ...
Healthline7y
Congenital Adrenal Hyperplasia: Types, Symptoms, and More - Healthline
Congenital adrenal hyperplasia (CAH) is a group of hereditary disorders that affect the adrenal glands. The adrenal glands produce the hormones cortisol and aldosterone. CAH is caused by genetic ...
WDAF-TV1y
Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia - FOX 4 Kansas City ...
SAN DIEGO, Dec. 5, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA ...